US2019224492A1PendingUtilityA1

System and method for optogenetic therapy

76
Assignee: CIRCUIT THERAPEUTICS INCPriority: Nov 21, 2012Filed: Apr 4, 2019Published: Jul 25, 2019
Est. expiryNov 21, 2032(~6.4 yrs left)· nominal 20-yr term from priority
A61P 9/12A61N 5/0622A61N 1/3605A61N 5/062A61N 1/0551A61B 2017/3413A61M 2037/0061A61K 38/168A61M 37/0015A61K 48/00A61N 5/0601A61K 48/0075A61K 38/164A61N 2005/0612A61B 17/3403A61N 2005/0631A61M 25/0147A61N 2005/0643A61N 2005/0626A61N 2005/063A61K 38/16A61M 5/142A61K 38/177A61N 2005/0627A61B 17/00234A61K 41/00A61K 41/0057A61M 5/20A61N 2005/0651A61N 2005/0653A61N 1/36053A61M 2205/50A61M 2037/0023A61N 2005/0665A61M 25/0105A61M 2205/3576A61N 2005/067A61N 5/067
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.

Claims

exact text as granted — not AI-modified
1 . A method for creating a directed action potential in a targeted nerve comprising light sensitive protein, comprising:
 a. providing a first implantable optical applicator configured to engage the targeted nerve and to deliver light to the targeted nerve, the first implantable optical applicator operatively coupled to a first light source configured to deliver photons to the first implantable optical applicator which may be emitted by the first implantable optical applicator into the targeted nerve to cause a membrane polarization change in the targeted nerve;   b. providing a second implantable optical applicator configured to engage the targeted nerve and to deliver light to the targeted nerve, the second implantable optical applicator operatively coupled to a second light source configured to deliver photons to the second implantable optical applicator which may be emitted by the second implantable optical applicator into the targeted nerve to cause a membrane polarization change in the targeted nerve; and   c. operatively coupling a controller to the first light source and the second light source, the controller configured to cause photons to be directed to each of the first and second implantable optical applicators, such that an action potential is created which propagates in a first desired direction along the nerve, and which does not substantially propagate in a reverse direction along the nerve.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.